Our Research Efforts
Bristol Myers Squibb is proactively taking steps to promote public health and carry out our mission of providing life-saving medicines to patients. We are helping to accelerate the development, manufacturing and delivery of diagnostics and treatments for COVID-19.
We have a global exclusive license to develop, manufacture and commercialize Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. The preclinical data suggest that this could enable effective treatment against multiple variants of the virus using a low dose subcutaneous administration, which would increase access to the medicine globally by eliminating the need for intravenous infusion. The mAb duo is part of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program and the Phase 2 trial (ACTIV-2) began enrolling in May 2021.
Additionally, as part of our contributions to the ACTIV program, Bristol Myers Squibb has also donated doses of apixaban (ACTIV-4) and abatacept (ACTIV-1) to NIH clinical trials assessing potential treatments for patients with COVID-19. Bristol Myers Squibb is also conducting real world data research to further advance potential treatment approaches of significant cardiovascular complications of COVID-19.
We are also participating in several cross-industry groups and public-private partnerships designed to foster collaboration and coordinate industry response efforts. We are one of 15 companies participating in the Bill & Melinda Gates Foundation’s COVID-19 Therapeutics Accelerator to identify concrete actions to accelerate treatments, vaccines and diagnostics. As part of this effort, Bristol Myers Squibb contributed more than 1,000 proprietary compounds to screen for possible molecules to treat COVID-19.
Bristol Myers Squibb organized and is leading a COVID-19 Testing Industry Consortium with 24 other healthcare companies that aims to inform, improve, innovate and accelerate various aspects of testing for COVID-19, ranging from research to clinical diagnostic applications.
While many patients are able to clear COVID-19 with few complications, some experience an inflammatory immune response that manifests as a “cytokine storm,” where pro-inflammatory cytokines and activated immune cells may lead to compromised organ function, including lung injury and/or acute respiratory distress syndrome (ARDS).
We evaluated compounds in our portfolio for potential clinical study that may have an impact on the inflammatory immune response associated with COVID-19, including abatacept. This research is advancing as company-sponsored and investigator-sponsored trials under the leadership of a Bristol Myers Squibb cross-functional team.
Our contributions to COVID-19 research reflect collaborative and productive discussions internally and with the broader life sciences community about how we can have the greatest impact given our company’s areas of strength, and we will continue to engage in this way in order to support the significant and rapid effort underway as the science evolves.
This page originally posted on November 2, 2020, and was most recently updated on September 7, 2021.